Loading...
XNAS
HBIO
Market cap26mUSD
Jun 10, Last price  
0.59USD
1D
6.50%
1Q
-13.20%
Jan 2017
-80.50%
IPO
-86.36%
Name

Harvard Bioscience Inc

Chart & Performance

D1W1MN
P/E
P/S
0.28
EPS
Div Yield, %
Shrs. gr., 5y
2.86%
Rev. gr., 5y
-4.12%
Revenues
94m
-16.14%
67,431,00076,181,00083,407,00088,049,00085,772,000108,179,000108,864,000111,171,000105,171,000108,663,000108,664,000104,521,000101,882,000120,774,000116,176,000102,100,000118,904,000113,335,000112,250,00094,135,000
Net income
-12m
L+263.25%
-31,877,000-2,341,000-1,354,0001,673,0007,233,00019,015,0003,812,0002,370,000-1,830,0002,355,000-19,039,000-4,307,000-865,000-3,462,000-4,687,000-7,810,000-288,000-9,516,000-3,415,000-12,405,000
CFO
1m
-89.73%
5,195,0008,356,00012,055,0009,202,00016,509,00012,293,0006,348,0008,062,0004,060,0004,351,000705,0005,383,0001,057,0002,344,0008,047,0009,331,0001,262,0001,152,00014,028,0001,440,000
Earnings
Aug 06, 2025

Profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
IPO date
Oct 21, 2013
Employees
436
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
94,135
-16.14%
112,250
-0.96%
113,335
-4.68%
Cost of revenue
93,480
104,831
114,379
Unusual Expense (Income)
NOPBT
655
7,419
(1,044)
NOPBT Margin
0.70%
6.61%
Operating Taxes
740
859
337
Tax Rate
112.98%
11.58%
NOPAT
(85)
6,560
(1,381)
Net income
(12,405)
263.25%
(3,415)
-64.11%
(9,516)
3,204.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,051)
BB yield
0.92%
Debt
Debt current
38,114
8,691
3,811
Long-term debt
13,920
41,708
50,430
Deferred revenue
Other long-term liabilities
1,255
1,476
6,288
Net debt
47,926
46,116
50,066
Cash flow
Cash from operating activities
1,440
14,028
1,152
CAPEX
(2,644)
(1,788)
(1,590)
Cash from investing activities
(1,344)
(1,799)
(1,590)
Cash from financing activities
(131)
(12,134)
(2,837)
FCF
170
1,446
3,171
Balance
Cash
4,108
4,283
4,508
Long term investments
(333)
Excess cash
Stockholders' equity
(173,680)
(159,361)
(156,788)
Invested Capital
282,770
278,100
282,120
ROIC
2.34%
ROCE
0.60%
6.21%
EV
Common stock shares outstanding
43,538
42,420
41,413
Price
2.11
-60.56%
5.35
93.14%
2.77
-60.71%
Market cap
91,865
-59.52%
226,947
97.84%
114,714
-59.67%
EV
139,791
273,063
164,780
EBITDA
7,812
14,417
6,531
EV/EBITDA
17.89
18.94
25.23
Interest
3,209
3,591
2,246
Interest/NOPBT
489.92%
48.40%